Navigation Links
Ampio Pharmaceuticals to List on the NYSE MKT
Date:6/6/2013

GREENWOOD VILLAGE, Colo., June 6, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it has received authorization from the NYSE Euronext (NYSE MKT) to transfer the listing from the NASDAQ Capital Market (NASDAQ).

(Logo:  http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

The Company expects its common stock to begin trading on the NYSE MKT on Monday, June 17, under its current ticker symbol, AMPE, and it will celebrate the transfer of its listing by ringing the opening bell at the New York Stock Exchange that morning. The company expects to continue to trade on NASDAQ until the transfer is complete.

Michael Macaluso , Chairman and CEO of Ampio, commented "We are very pleased to join other strong and growing life science companies on the NYSE community. We feel that transferring the listing of our common stock to NYSE MKT will result in better visibility to the financial and medical community, while improving our liquidity and decreasing our volatility."

"We welcome Ampio Pharmaceuticals to the NYSE community family of listed companies," said Scott Cutler , Executive Vice President, Global Listings at NYSE Euronext. "Ampio will be joining other growth oriented companies that have chosen our advanced and innovative market model to offer a premier venue for the listing and trading of their stock.  We look forward to our partnership with Ampio and its shareholders."

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals Provides Clinical Updates
2. Synergy Health Wins Practice Green Health Champion for Change Award
3. Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
4. Former NBA Champion John Salley Partners With Watertree Health To Promote Free Prescription Discount Card
5. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
6. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
7. Americans United for Life Celebrates Win for Illinois Conscience Rights in Case AUL Championed Since 2005
8. Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
9. Novation Champions Reusable Packaging for Sustainability in Healthcare
10. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
11. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... Israel , May 4, 2016 ... today that BiondVax,s CEO, Dr. Ron Babecoff , will ... New York City . On Thursday, ... Pioneers 2016, a conference presented by Joseph Gunner ... The BiondVax presentation that Dr. Babecoff will be ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of ... deep dive on NCPDP’s model solution to help stem the tide of the ...
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute announces ... of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses ... 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are raising ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, ... Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful ... planning tools to attendees and exhibitors for the 2016 WOCN Society & CAET ...
(Date:5/4/2016)... , ... May 04, 2016 , ... May kicked off ... people across the United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as ... advice and focus on skin safety and health now and in the future. , ...
(Date:5/4/2016)... MO (PRWEB) , ... May 04, 2016 , ... Recognizing ... newly launched health brand, Verywell, have tapped David Katz, MD, MPH, president ... , “Our shared devotion to lifestyle medicine is especially gratifying,” said Katz. “There ...
Breaking Medicine News(10 mins):